Nehal R. Patel, M.D.

Nehal R. Patel, M.D.Ophthalmic Gulf Coast Eye Institute
1205 Ed Carey Drive
Harlingen, TX 78550
(956) 320-7510

Education and Training

  • Vitreoretinal Fellowship: University of Nebraska Medical Center Omaha, NE
  • Ophthalmology Residency:University of Nebraska Medical Center Omaha, NE
  • Internship in General Surgery: University of Nebraska Medical Center Omaha, NE
  • Glaucoma Fellowship: University of Nebraska Medical Center Omaha, NE
  • Ophthalmology Residency: University of Bombay, Nair Hospital Bombay, India
  • Medical School: University of Bombay, Grant Medical College Bombay, India Distinction in ENT and Ophthalmology
  • Undergraduate Education: University of Bombay, Jai Hind College Bombay, India

Clinical Research

  • Sub-Investigator - A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD). Protocol ACU301C. Closed
  • Sub-Investigator- A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME). Protocol Number 206207-012-00. Active
  • Sub-Investigator- A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-0605. Active.
  • Sub-Investigator- A Trial to Assess the safety and Tolerability of repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-OD-0603. Active.
  • Sub-Investigator- A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration (AMD). Protocol JO642701. Active.
  • Sub-Inestigator- A Mutlicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel-Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial. Protocol TG-MV-003. Closed
  • Sub-Investigator- Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion. Version 3.1. Dated 30 July 2004. Closed.
  • Sub-Investigator- An Open Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Chorodial Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) who have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study. Protocol FVF3426g. Closed
  • Sub-Investigator- A Phase I, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and E10030 Given in Combination with Lucentis 0.5 MG/EYE in Subjects with Neovascular Age Related Macular Degeneration. Protocol OPH1000. Active.
  • Sub-Investigator- A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects with Diffuse Diabetic Macular Edema. Protocol 2006-007-01-DME. Active.
  • Sub-Investigator- A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema. Protocol C-01-05-001 Active
  • All Day Clinical Conference, Doheny Eye Institute, Los Angeles, CA, December 1989. "Current Approach and Treatment of Vernal Conjunctivitis."
  • Sub-Investigator-A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial Of Micrplasmin Intravitreal Injection For Non-Surgical Treatment of Focal Vitreomacular Adhesion. TG-MV-006. Active
  • Sub-Investigator-A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Protocol FVF4170g. Active.
  • Sub-Investigator- A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-0605. Active.
  • Sub-Investigator-A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME). Protocol Number 206207-012-00. Active
  • Principal Investigator – Protocol J/DRCR Net. Intravitreal Ranizumab or Triamcinolone Acetonide as Adjunction Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Active.
  • Effectiveness, safety and tolerability of DR608, in the management of early diabetic retinopathy. Active